---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-016821"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:12:38.145319+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Pulse Biosciences appoints Burke T. Barrett as CEO; Kevin Danahy becomes Chief Commercial Officer

## Summary
- Burke T. Barrett named President and CEO effective May 12, 2024; succeeds Kevin Danahy who becomes Chief Commercial Officer.
- Barrett previously CEO of CardioFocus, led global commercial launch of atrial fibrillation laser-balloon ablation device.
- Barrett receives options to purchase 1.4M shares at $7.45, half time-vested over 4 years, half upon $1B-$4B market cap milestones.
- Danahy and CTO Darrin Uecker amend employment agreements to reduce severance salary continuation from 12 to 3 months (12 months post-change of control).

## SEC filing metadata
- accession: 0001437749-24-016821
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000143774924016821/0001437749-24-016821-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000143774924016821/plse20240513_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-016821
- JSON: https://secwatch.observer/filing/0001437749-24-016821.json
- Plain text: https://secwatch.observer/filing/0001437749-24-016821.txt

## Key facts
- Executive change
  Burke T. Barrett was appointed as President and Chief Executive Officer at PULSE BIOSCIENCES, INC..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: The Board of Directors of Pulse Biosciences, Inc. (the “Company”) has appointed Burke T. Barrett as President and Chief Executive Officer of the Company and as a director, in each case effective as of May 12, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1625101/000143774924016821/0001437749-24-016821-index.htm
- Executive change
  Burke T. Barrett was appointed as Director at PULSE BIOSCIENCES, INC..
  - Action: appointed
  - Role: Director
  source text: The Board of Directors of Pulse Biosciences, Inc. (the “Company”) has appointed Burke T. Barrett as President and Chief Executive Officer of the Company and as a director, in each case effective as of May 12, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1625101/000143774924016821/0001437749-24-016821-index.htm
- Executive change
  Kevin P. Danahy was appointed as Chief Commercial Officer at PULSE BIOSCIENCES, INC..
  - Action: appointed
  - Role: Chief Commercial Officer
  source text: Mr. Barrett succeeds Kevin P. Danahy, who was appointed as the Company’s Chief Commercial Officer, as of the Start Date
  evidence_url: https://www.sec.gov/Archives/edgar/data/1625101/000143774924016821/0001437749-24-016821-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.